Multiple Sclerosis (MS) - Relapsing-remitting

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
UblituximabN/AMonoclonal Antibody1 trial
Active Trials
NCT06864936Not Yet RecruitingEst. Jun 2027

Trial Timeline

Clinical trial activity over time

2026
2027
TG TherapeuticsUblituximab

Clinical Trials (1)

NCT06864936TG TherapeuticsUblituximab

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

Start: Jan 2026Est. completion: Jun 2027
N/ANot Yet Recruiting

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
8h ago

Director of Finance

CoMind
London, UK
8h ago

Electronics Engineering Manager

CoMind
London, UK
8h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)